|
Hemato-oncology
Geriatric risk model for older patients with diffuse large B-cell lymphoma (GERIAD): a prospective multicenter cohort study
Ho-Young Yhim, Yong Park, Jeong-A Kim, Ho-Jin Shin, Young Rok Do, Joon Ho Moon, Min Kyoung Kim, Won Sik Lee, Dae Sik Kim, Myung-Won Lee, Yoon Seok Choi, Seong Hyun Jeong, Kyoung Ha Kim, Jinhang Kim, Chang-Hoon Lee, Ga-Young Song, Deok-Hwan Yang, Jae-Yong Kwak
Korean J Intern Med. 2024;39(3):501-512. Published online January 30, 2024
Background/Aims: Optimal risk stratification based on simplified geriatric assessment to predict treatment-related toxicity and survival needs to be clarified in older patients with diffuse large B-cell lymphoma (DLBCL).
Methods: This multicenter prospective cohort study enrolled newly diagnosed pat..
|
|
|
Identification and overcoming rituximab resistance in diffuse large B-cell lymphoma using next-generation sequencing
Min Ji Jeon, Eun Sang Yu, Chul Won Choi, Dae Sik Kim
Korean J Intern Med. 2023;38(6):893-902. Published online August 21, 2023
Background/Aims: Although rituximab, an antiCD20 monoclonal antibody, has dramatically improved the clinical outcomes of diffuse large B-cell lymphoma, rituximab resistance remains a challenge.
Methods: We developed a rituximab-resistant cell line (RRCL) by sequential exposure to gradually increasi..
|
|
|
Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells
Yoo Jin Na, Eun Sang Yu, Dae Sik Kim, Dae-Hee Lee, Sang Cheul Oh, Chul Won Choi
Korean J Intern Med. 2021;36(Suppl 1):S196-S206. Published online April 3, 2020
Background/Aims: Nilotinib is used for treating patients with imatinib-sensitive or -resistant chronic myeloid leukemia (CML); however, nilotinib-resistant cases have been observed in recent years. In addition, a considerable number of patients receiving nilotinib developed diabetes. Metformin is a ..
|
|
|
The effect of the response to the coronavirus disease pandemic on treatment outcomes in patients with lymphoma and multiple myeloma
Ka-Won Kang, Byung-Hyun Lee, Min Ji Jeon, Eun Sang Yu, Dae Sik Kim, Se Ryeon Lee, Hwa Jung Sung, Chul Won Choi, Yong Park, Byung Soo Kim
Korean J Intern Med. 2021;36(6):1459-1470. Published online October 21, 2021
Background/Aims: Relatively little data are available on how the response to the coronavirus disease 2019 (COVID-19) pandemic has affected treatment outcomes in patients receiving chemotherapy for lymphoma or multiple myeloma. We aimed to determine the effect of COVID-19 countermeasures on treatment..
|
|
|
The role of platelet function analyzer-200 in predicting perioperative bleeding risk
Eun Sang Yu, Min Ji Jeon, Ka-Won Kang, Byung-Hyun Lee, Eun Joo Kang, Yong Park, Se Ryeon Lee, Hwa Jung Sung, Chul Won Choi, Byung Soo Kim, Dae Sik Kim
Korean J Intern Med. 2020;35(5):1199-1209. Published online February 6, 2020
Background/Aims: Various preoperative screening tests, such as platelet count, prothrombin time, activated partial thromboplastin time, and bleeding time, have been widely used to evaluate the risk of bleeding during surgery. Use of platelet function analyzer (PFA)-100/200 for assessing platelet fun..
|
|
|
Immature platelet fraction based diagnostic predictive scoring model for immune thrombocytopenia
Min Ji Jeon, Eun Sang Yu, Ka-Won Kang, Byung-Hyun Lee, Yong Park, Se Ryeon Lee, Hwa Jung Sung, Soo Yong Yoon, Chul Won Choi, Byung Soo Kim, Dae Sik Kim
Korean J Intern Med. 2020;35(4):970-978. Published online April 10, 2020
Background/Aims: The diagnosis of immune thrombocytopenia (ITP) is based on clinical manifestations and there is no gold standard. Thus, even hematologic malignancy is sometimes misdiagnosed as ITP and adequate treatment is delayed. Therefore, novel diagnostic parameters are needed to distinguish IT..
|
|
|
Inflammatory markers as prognostic indicators in pancreatic cancer patients who underwent gemcitabine-based palliative chemotherapy
Hong Jun Kim, Suk-young Lee, Dae Sik Kim, Eun Joo Kang, Jung Sun Kim, Yoon Ji Choi, Sang Cheul Oh, Jae Hong Seo, Jun Suk Kim
Korean J Intern Med. 2020;35(1):171-184. Published online October 26, 2018
Background/Aims: Patients with pancreatic cancer (PC) generally have poor clinical outcomes. Early determination of their prognosis is crucial for developing a therapeutic strategy. Recently, various inflammatory markers have been validated as prognostic indicators for many cancers, including PC. Ho..
|
|
|
Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
Se Ryeon Lee, Hojoon Choi, Byung Hyun Lee, Ka-Won Kang, Eun Sang Yu, Dae Sik Kim, Yong Park, Chul Won Choi, Byung Soo Kim, Hwa Jung Sung
Korean J Intern Med. 2019;34(6):1333-1346. Published online October 26, 2018
Background/Aims: Bortezomib plus melphalan-prednisone (VMP) is a standard treatment for multiple myeloma, particularly for patients who are ineligible for high-dose therapy. However, early discontinuation or treatment modification is often needed owing to adverse events. The aim of this study was to..
|
|
|
|
|
Hemato-oncology
Myeloma prognostic index at diagnosis might be a prognostic marker in patients newly diagnosed with multiple myeloma
Dae Sik Kim, Eun Sang Yu, Ka-Won Kang, Se Ryeon Lee, Yong Park, Hwa Jung Sung, Chul Won Choi, Byung Soo Kim
Korean J Intern Med. 2017;32(4):711-721. Published online November 4, 2016
Background/Aims: The aims of this study were to identify the value of inflammatory markers as pretreatment prognostic factors for patients with multiple myeloma (MM) and to estimate the value of a prognostic index including these markers at diagnosis.
Methods: A total of 273 newly diagnosed MM pati..
|
|
|
Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells
Dae Sik Kim, Yoo Jin Na, Myoung Hee Kang, Soo-Young Yoon, Chul Won Choi
Korean J Intern Med. 2016;31(2):357-366. Published online February 15, 2016
Background/Aims: The treatment of chronic myeloid leukemia (CML) has achieved impressive success since the development of the Bcr-Abl tyrosine kinase inhibitor, imatinib mesylate. Nevertheless, resistance to imatinib has been observed, and a substantial number of patients need alternative treatment ..
|
|
|
